Acute Myeloid Leukemia (Nursing)

Anusha Vakiti; Samuel Reynolds; Prerna Mewawalla

Acute Myeloid Leukemia (Nursing)

Learning Outcome

Recall the etiology and risk factors for AML
Describe the presentation of AML
Summarize the treatment of AML
List the nursing diagnosis of AML

Introduction

Acute myeloid leukemia (AML) is the most common leukemia among the adult population and accounts for about 80% of all cases. It is characterized by clonal expansion of immature “blast cells” in the peripheral blood and bone marrow resulting in ineffective erythropoiesis and bone marrow failure. With recent advancements in the management guidelines, the cure rates have increased up to 15% in patients older than 60 years and about 40% in patients below 60 years of age. Despite advancements in therapeutic regimens, the prognosis remains very poor in the elderly population.[1][2][3]

Nursing Diagnosis

Anorexia
Fatigue, malaise
Weakness
Bruising
Bone pain
Fever
Frequent infections
Nose bleeds

Causes

Depending upon the etiology, genetics, immune-phenotype, and morphology, there are different classification systems for AML.[4][5]

In the past, French-American-British system classified AML into eight subtypes, FAB M0 to M7 which are as follows:

M0: Undifferentiated AML
M1: AML with minimal maturation
M2: AML with maturation
M3: Acute promyelocytic leukemia (APL)
M4: Acute myelomonocytic leukemia
M5: Acute monocytic leukemia
M6: Acute erythroid leukemia
M7: Acute megakaryocytic leukemia

In 2016, World Health Organization (WHO) revised the classification and categorized it into AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related myeloid neoplasms, NOS, myeloid sarcoma, myeloid proliferations related to Down syndrome.

AML with recurrent genetic abnormalities includes-

AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
APL with t(15;17)(q22;q12); PML-RARA
AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A
AML with t(6;9)(p23;q24); DEK-NUP214
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1
AML with mutated NPM1
AML with biallelic mutations CEBPA

AML not otherwise specified (NOS) includes:

AML with minimal differentiation
AML without maturation
AML with maturation
Acute myelomonocytic leukemia
Acute monoblastic/monocytic leukemia
Pure erythroid leukemia
Acute megakaryoblastic leukemia
Acute basophilic leukemia
Acute panmyelosis with myelofibrosis

Based on the etiology of the AML, it can be categorized into de novo AML, Secondary AML (s-AML) which evolves from prior MPD or MDS and Therapy related AML (t-AML) following exposure to chemotherapeutic agents or radiation therapy or toxins.

Risk Factors

The number of new cases among men and women per year is about 4.2 per 100,000 population. The incidence is over 20,000 cases per year in the United States. The average age at the time of diagnosis is about 65 years. It is more prevalent among non-Hispanic whites. Males have more predominance compared to females with a ratio of 5:3.

Assessment

Due to ineffective erythropoiesis and bone marrow failure, patients experience a variety of symptoms including recurrent infections, anemia, easy bruising, excessive bleeding, headaches, and bone pains. Depending on the degree of anemia, they can experience generalized weakness, fatigue, shortness of breath and chest tightness. Physical examination can reveal bruises, pallor, hepatomegaly, and splenomegaly. Lymphadenopathy is rare. DIC is common in patients with APL.

Evaluation

AML should be suspected in anyone with unexplained cytopenias (decreased cell count of white blood cells, hemoglobin or platelets), the presence of circulating blast cells in the peripheral blood, easy bruising or bleeding or recurrent infections. In some cases, they can present with renal failure secondary to tumor lysis syndrome which is an oncologic emergency.[6][7][8][9]

Presence of at least 20% blasts in the bone marrow or peripheral blood is diagnostic of AML. It can be diagnosed with bone marrow aspiration and biopsy. Additional diagnostics include flow cytometry, cytogenetics, and fluorescence in situ hybridization (FISH). Presence of Auer rods (clumps of azurophilic granules resembling elongated needles) is diagnostic of AML. Auer rods can be seen in many subtypes of AML, but abundantly seen in APL.

Oncologic emergencies associated with AML include neurologic or respiratory distress due to leukostasis, APL-induced DIC, tumor lysis syndrome, and central nervous system (CNS) involvement.[10]

Medical Management

Individuals who achieve complete remission (CR) with a blast count of less than 5% in the bone marrow after induction therapy tend to have increased survival. Despite induction therapy, there is still minimal residual disease for which consolidation therapy is initiated to prevent any risk of relapse by eliminating the residual disease. Despite many advances, the mainstay of therapy remains a combination of cytarabine-based and anthracycline-based regimens. For eligible candidates, allogeneic stem cell transplantation should be considered.[11][12][13][14]

Induction Therapy

This is a standard of care for younger patients, elderly with low risk of treatment-related mortality (TRM), and ones with favorable and intermediate-risk factors. The induction therapy is highly toxic to bone marrow causing pancytopenias and bleeding complications, gastrointestinal system issues, kidney failure due to tumor lysis syndrome, and electrolyte disturbances. It may take up to 1 month for the cell counts to recover, and these patients need aggressive monitoring to manage any complications. Baseline cardiac function should be estimated before initiating the treatment, and the ejection fraction (EF) needs to be monitored carefully, as anthracyclines can cause significant cardiotoxicity. Studies have shown greater benefit with higher doses, but toxicities may limit its use. It consists of "7+3" regimen that includes continuous infusion of cytarabine for seven days along with anthracycline on days 1 to 3. Patients with the refractory disease have shown higher CR and similar overall survival (OS) by using higher doses of cytarabine or by using a combination of fludarabine, cytarabine, and idarubicin. Despite TRM in elderly, chemotherapy has shown to improve the survival rate among elderly (older than 65 years). Decitabine, a methylating agent, used in the treatment of MDS, has shown improvement in OS in the elderly population. The response should be evaluated by repeating the bone marrow aspirate and biopsy after 2 weeks of initiating the induction therapy. Reinduction can be done with high dose cytarabine or by combining with etoposide if there is persistent evidence of disease. About 60% to 80% de novo AML will achieve CR with induction therapy.

Even before the diagnosis, if APL is suspected, then the treatment should be initiated with all-trans retinoic acid (ATRA), as early use of ATRA decreases the risk of disseminated intravascular coagulation (DIC) and mortality associated with it.

Consolidation Therapy

After achieving CR with induction therapy, consolidation therapy is initiated with high dose cytarabine, called HiDAC and hematopoietic cell transplantation (HCT). HCT is preferred in individuals with less than 60 years of age with intermediate or unfavorable prognosis. If a donor is available, then allogenic HCT is preferred over autologous HCT. They should be Monitored for signs or symptoms of acute or chronic graft versus host disease (GVHD).

Novel Targets

Ongoing studies with Fms-like tyrosine kinase 3 (FLT3) inhibitors, IDH inhibitors, and immune therapies.

Nursing Management

Check labs for coagulation parameters
Check vitals
Provide skin protection
Monitor for infection and sepsis
Promote normothermia
Educate the patient and family
Monitor ins and outs
Check if nutrition is sufficient
Promote hand washing
Encourage self care

When To Seek Help

Fever
Hypotension
Bleeding
LOC
Altered mental status
Severe bruising
Pain

Outcome Identification

Normal appetite
Vitals stable
No signs of infection
Afebrile
No pain

Monitoring

Vitals
Ins and outs
Body weight
Neurovitals
Dehydration
Nutrition
Signs of infection

Coordination of Care

AML is a common hematological malignancy in adults. Despite many advances, the malignancy still carries a poor prognosis. Hence, it is best managed by a multidisciplinary team that includes a hematologist, oncologist. internist, pathologist, and an intensivist. The oncology nurse is vital for treatment administration and monitoring for potential complications. The pharmacist should educate the patient on potential adverse effects of the potent drugs used to treat this malignancy. The primary care physician should educate the patient on personal hygiene, hand washing, and immunization. Overall, the life expectancy has increased slightly but most patients have a markedly shortened lifespan.[15][16]

Health Teaching and Health Promotion

Wash hands
Rinse all fruits and vegetables
Avoid crowds
Maintain good personal hygiene
Follow up with a clinician
Take medications as prescribed

Discharge Planning

Wash hands
Rinse all fruits and vegetables
Avoid crowds
Maintain good personal hygiene
Follow up with clinician
Take medications as prescribed

Pearls and Other issues

AML is a common hematological malignancy in adults. Despite many advances, the malignancy still carries a poor prognosis. Hence, it is best managed by an interprofessional team that includes a hematologist, oncologist. internist, pathologist, and an intensivist. The key is to prevent more harm to the patient and hence a universal treatment plan must be developed and carried out.

The pharmacist should educate the patient on the chemotherapeutic drugs, their benefits, and adverse effects. The oncology nurse is vital for treatment administration and monitoring for potential complications.

The nurse should educate the patient on infection prevention by washing hands, rinsing all fruits and vegetables, avoiding crowds and seeking help at the first sign of fever.

The radiologist is essential for placement of long term venous catheters and other imaging studies. The primary care physician should educate the patient on personal hygiene, hand washing, and immunization. The dietitian should help manage nutrition and the social work should ensure that the patient has all the support to complete the treatment.

Details

References

[1]

Bain BJ, Béné MC. Morphological and Immunophenotypic Clues to the WHO Categories of Acute Myeloid Leukaemia. Acta haematologica. 2019:141(4):232-244. doi: 10.1159/000496097. Epub 2019 Apr 9 [PubMed PMID: 30965338]

[2]

Naymagon L, Marcellino B, Mascarenhas J. Eosinophilia in acute myeloid leukemia: Overlooked and underexamined. Blood reviews. 2019 Jul:36():23-31. doi: 10.1016/j.blre.2019.03.007. Epub 2019 Mar 30 [PubMed PMID: 30948162]

[3]

Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. American journal of hematology. 2019 Jul:94(7):803-811. doi: 10.1002/ajh.25484. Epub 2019 May 1 [PubMed PMID: 30945331]

[4]

Hartmann L, Metzeler KH. Clonal hematopoiesis and preleukemia-Genetics, biology, and clinical implications. Genes, chromosomes & cancer. 2019 Dec:58(12):828-838. doi: 10.1002/gcc.22756. Epub 2019 Apr 16 [PubMed PMID: 30939217]

[5]

Boddu PC, Zeidan AM. Myeloid disorders after autoimmune disease. Best practice & research. Clinical haematology. 2019 Mar:32(1):74-88. doi: 10.1016/j.beha.2019.02.002. Epub 2019 Feb 7 [PubMed PMID: 30927978]

[6]

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22:140(12):1345-1377. doi: 10.1182/blood.2022016867. Epub [PubMed PMID: 35797463]

[7]

Platzbecker U. Treatment of MDS. Blood. 2019 Mar 7:133(10):1096-1107. doi: 10.1182/blood-2018-10-844696. Epub 2019 Jan 22 [PubMed PMID: 30670446]

[8]

Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gökbuget N, Gotlib J, Hellström-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Löwenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Döhner H, Tefferi A. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15:140(11):1200-1228. doi: 10.1182/blood.2022015850. Epub [PubMed PMID: 35767897]

[9]

Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood advances. 2017 Jul 25:1(17):1312-1323. doi: 10.1182/bloodadvances.2017008227. Epub 2017 Jul 19 [PubMed PMID: 29296774]

[10]

Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kündgen A, Götze K, Rummel M, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Zucknick M, Ganser A, Döhner H, Schlenk RF, German-Austrian AMLSG. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011 Feb 17:117(7):2137-45. doi: 10.1182/blood-2010-08-301713. Epub 2010 Dec 2 [PubMed PMID: 21127174]

[11]

Menghrajani K, Zhang Y, Famulare C, Devlin SM, Tallman MS. Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes. Leukemia research. 2020 Nov:98():106453. doi: 10.1016/j.leukres.2020.106453. Epub 2020 Sep 16 [PubMed PMID: 33059120]

[12]

Chelghoum Y, Danaïla C, Belhabri A, Charrin C, Le QH, Michallet M, Fiere D, Thomas X. Influence of cigarette smoking on the presentation and course of acute myeloid leukemia. Annals of oncology : official journal of the European Society for Medical Oncology. 2002 Oct:13(10):1621-7 [PubMed PMID: 12377652]

[13]

Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood reviews. 2019 Jul:36():70-87. doi: 10.1016/j.blre.2019.04.005. Epub 2019 Apr 29 [PubMed PMID: 31101526]

[14]

Ranieri R, Pianigiani G, Sciabolacci S, Perriello VM, Marra A, Cardinali V, Pierangeli S, Milano F, Gionfriddo I, Brunetti L, Martelli MP, Falini B. Current status and future perspectives in targeted therapy of NPM1-mutated AML. Leukemia. 2022 Oct:36(10):2351-2367. doi: 10.1038/s41375-022-01666-2. Epub 2022 Aug 25 [PubMed PMID: 36008542]

[15]

Liu XJ, Huang XJ, Xu LP, Liu KY, Zhang XH, Yan CH, Wang Y. [Effects of pre-transplant course on prognosis of allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2019 Mar 14:40(3):182-186. doi: 10.3760/cma.j.issn.0253-2727.2019.03.003. Epub [PubMed PMID: 30929382]

[16]

Leisch M, Jansko B, Zaborsky N, Greil R, Pleyer L. Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation? Cancers. 2019 Feb 21:11(2):. doi: 10.3390/cancers11020252. Epub 2019 Feb 21 [PubMed PMID: 30795628]

[17]

Dong XY, Li YL, Jiang L, Wu CY, Shang BJ, Zhang L, Cheng W, Zhu ZM. [Correlation between myeloperoxidase expression and gene alterations and prognosis in acute myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2019 Jan 14:40(1):40-45. doi: 10.3760/cma.j.issn.0253-2727.2019.01.008. Epub [PubMed PMID: 30704227]

[18]

Schmid C, Labopin M, Schaap N, Veelken H, Schleuning M, Stadler M, Finke J, Hurst E, Baron F, Ringden O, Bug G, Blaise D, Tischer J, Bloor A, Esteve J, Giebel S, Savani B, Gorin NC, Ciceri F, Mohty M, Nagler A, EBMT Acute Leukaemia Working Party. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. British journal of haematology. 2019 Mar:184(5):782-787. doi: 10.1111/bjh.15691. Epub 2018 Nov 22 [PubMed PMID: 30467839]

[19]

Nabhan C, Kamat S, Karl Kish J. Acute myeloid leukemia in the elderly: what constitutes treatment value? Leukemia & lymphoma. 2019 May:60(5):1164-1170. doi: 10.1080/10428194.2018.1520992. Epub 2018 Nov 8 [PubMed PMID: 30407103]

[20]

Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Anthracycline dose intensification in acute myeloid leukemia. The New England journal of medicine. 2009 Sep 24:361(13):1249-59. doi: 10.1056/NEJMoa0904544. Epub [PubMed PMID: 19776406]

[21]

Cheung E, Perissinotti AJ, Bixby DL, Burke PW, Pettit KM, Benitez LL, Brown J, Scappaticci GB, Marini BL. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Annals of hematology. 2019 Mar:98(3):541-559. doi: 10.1007/s00277-019-03606-0. Epub 2019 Jan 21 [PubMed PMID: 30666431]

[22]

Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl AE, Sekeres MA, Dombret H, Amadori S, Wang J, Levis MJ, Schlenk RF, QuANTUM-First Study Group. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2023 May 13:401(10388):1571-1583. doi: 10.1016/S0140-6736(23)00464-6. Epub 2023 Apr 25 [PubMed PMID: 37116523]

[23]

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. The New England journal of medicine. 2020 Aug 13:383(7):617-629. doi: 10.1056/NEJMoa2012971. Epub [PubMed PMID: 32786187]

[24]

Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 Apr 11:133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25 [PubMed PMID: 30803991]

[25]

Duan WB, Gong LZ, Jia JS, Zhu HH, Zhao XS, Jiang Q, Zhao T, Wang J, Qin YZ, Huang XJ, Jiang H. [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences. 2017 Dec 18:49(6):990-995 [PubMed PMID: 29263470]

[26]

Lin M, Chen B. Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia). Drug design, development and therapy. 2018:12():1009-1017. doi: 10.2147/DDDT.S161199. Epub 2018 Apr 30 [PubMed PMID: 29750014]

[27]

Schoen MW, Woelich SK, Braun JT, Reddy DV, Fesler MJ, Petruska PJ, Freter CE, Lionberger JM. Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk. Leukemia research. 2018 May:68():72-78. doi: 10.1016/j.leukres.2018.03.005. Epub 2018 Mar 6 [PubMed PMID: 29574395]

[28]

Strickland SA, Shaver AC, Byrne M, Daber RD, Ferrell PB, Head DR, Mohan SR, Mosse CA, Moyo TK, Stricker TP, Vnencak-Jones C, Savona MR, Seegmiller AC. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. Leukemia research. 2018 Feb:65():67-73. doi: 10.1016/j.leukres.2017.12.012. Epub 2018 Jan 2 [PubMed PMID: 29310020]

[29]

. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. The New England journal of medicine. 2022 May 12:386(19):1868. doi: 10.1056/NEJMx220003. Epub [PubMed PMID: 35544407]

[30]

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. The New England journal of medicine. 2018 Jun 21:378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2 [PubMed PMID: 29860938]

[31]

de Botton S, Fenaux P, Yee K, Récher C, Wei AH, Montesinos P, Taussig DC, Pigneux A, Braun T, Curti A, Grove C, Jonas BA, Khwaja A, Legrand O, Peterlin P, Arnan M, Blum W, Cilloni D, Hiwase DK, Jurcic JG, Krauter J, Thomas X, Watts JM, Yang J, Polyanskaya O, Brevard J, Sweeney J, Barrett E, Cortes J. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood advances. 2023 Jul 11:7(13):3117-3127. doi: 10.1182/bloodadvances.2022009411. Epub [PubMed PMID: 36724515]

[32]

Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10:130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6 [PubMed PMID: 28588020]

[33]

Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C, Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner EM, Kröger N, Wolschke C, Schleuning M, Götze KS, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A, Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Sep 10:38(26):2993-3002. doi: 10.1200/JCO.19.03345. Epub 2020 Jul 16 [PubMed PMID: 32673171]

[34]

Fujiwara Y, Yamaguchi H, Yui S, Tokura T, Inai K, Onai D, Omori I, Marumo A, Yamanaka S, Sakaguchi M, Terada K, Nakagome S, Arai K, Kitano T, Okabe M, Okamoto M, Tamai H, Nakayama K, Tajika K, Wakita S, Inokuchi K. Importance of prognostic stratification via gene mutation analysis in elderly patients with acute myelogenous leukemia. International journal of laboratory hematology. 2019 Aug:41(4):461-471. doi: 10.1111/ijlh.13025. Epub 2019 Apr 10 [PubMed PMID: 30970181]

[35]

Niu P, Yao B, Wei L, Zhu H, Fang C, Zhao Y. Construction of prognostic risk prediction model based on high-throughput sequencing expression profile data in childhood acute myeloid leukemia. Blood cells, molecules & diseases. 2019 Jul:77():43-50. doi: 10.1016/j.bcmd.2019.03.008. Epub 2019 Mar 28 [PubMed PMID: 30954792]